The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Product Name	NDC(s)	Lot(s)/ Batch	Exp
Amlodipine and Olmesartan Medoxomil Tablets 10 mg + 20 mg	**33342-192-07**	**BAD62101A**	**02/2024**

Macleods Pharmaceuticals Limited is extending the recall of Amlodipine and Olmesartan Medoxomil Tablets 10 mg + 20 mg from Wholesale level to Retail level. This recall is based upon inadequate investigation for Out of Specification result for Assay for Amlodipine content (93.7%) against the specification limit (NLT 95.0 & NMT 105.0%) during lubricated blend sample analysis (composite stage) of above batch. The other component, Olmesartan Medoxomil results were 95.4 % within the specification.

The batch was distributed during the period of 25 August 2021 until 31 January 2022.